BioLineRx GAAP EPS of $0.00 beats by $0.07, revenue of $4.94M misses by $0.35M

seekingalpha

25 Nov 2024

BioLineRx press release (NASDAQ:BLRX): Q3 GAAP EPS of $0.00 beats by $0.07.
Revenue of $4.94M misses by $0.35M.
As of September 30, 2024, the company had cash, cash equivalents, and short-term bank deposits of $29.2 million.
Following the out-license to Ayrmid, the equity investment from Highbridge and the debt repayment to Blackrock, the Company's cash, cash equivalents and short-term bank deposits are expected to be approximately $20 million, which management believes will be sufficient to fund operations into 2026, as currently planned

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2486853083"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2486853083\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2486853083?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-25 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486853083","market":"other","top_or_hot":-1,"title":"BioLineRx GAAP EPS of $0.00 beats by $0.07, revenue of $4.94M misses by $0.35M","media":"seekingalpha","content":"<html><body><ul> <li>BioLineRx press release (<span>NASDAQ:BLRX</span>): Q3 GAAP EPS of $0.00 <span> beats by $0.07</span>.</li> <li>Revenue of $4.94M <span> misses by $0.35M</span>.</li> <li>As of September 30, 2024, the company had cash, cash equivalents, and short-term bank deposits of $29.2 million.</li> <li>Following the out-license to<span> Ayrmid, the equity investment from Highbridge and the debt repayment to Blackrock, the Company's cash, cash equivalents and short-term bank deposits are expected to be approximately $20 million, which management believes will be sufficient to fund operations into 2026, as currently planned</span> </li> </ul> </body></html>","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioLineRx GAAP EPS of $0.00 beats by $0.07, revenue of $4.94M misses by $0.35M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioLineRx GAAP EPS of $0.00 beats by $0.07, revenue of $4.94M misses by $0.35M\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-25 20:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4329101-biolinerx-gaap-eps-of-000-beats-by-007-revenue-of-494m-misses-by-035m><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioLineRx press release (NASDAQ:BLRX): Q3 GAAP EPS of $0.00  beats by $0.07. Revenue of $4.94M  misses by $0.35M. As of September 30, 2024, the company had cash, cash equivalents, and short-term bank ...</p>\n\n<a href=\"https://seekingalpha.com/news/4329101-biolinerx-gaap-eps-of-000-beats-by-007-revenue-of-494m-misses-by-035m\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLRX","symbol_name":"BioLine Rx","start_time":0,"source_url":"https://seekingalpha.com/news/4329101-biolinerx-gaap-eps-of-000-beats-by-007-revenue-of-494m-misses-by-035m","article_id":"2486853083","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486853083","pubTimestamp":1732536257,"columns":[],"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"BioLineRx press release : Q3 GAAP EPS of $0.00  beats by $0.07. Revenue of $4.94M  misses by $0.35M. As of September 30, 2024, the company had cash, cash equivalents, and short-term bank deposits of $29.2 million. Following the out-license to Ayrmid, the equity investment from Highbridge and the debt repayment to Blackrock, the Company's cash, cash equivalents and short-term bank deposits are expected to be approximately $20 million, which management believes will be sufficient to fund operations into 2026, as currently planned","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BLRX":"BioLine Rx"},"translate_title":"BioLineRx GAAP每股收益为0.00美元超过预期0.07美元，收入为494万美元低于预期35万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLRX":0.9},"content_text":"BioLineRx press release (NASDAQ:BLRX): Q3 GAAP EPS of $0.00  beats by $0.07. Revenue of $4.94M  misses by $0.35M. As of September 30, 2024, the company had cash, cash equivalents, and short-term bank deposits of $29.2 million. Following the out-license to Ayrmid, the equity investment from Highbridge and the debt repayment to Blackrock, the Company's cash, cash equivalents and short-term bank deposits are expected to be approximately $20 million, which management believes will be sufficient to fund operations into 2026, as currently planned","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}